INVESTORS & MEDIA

CAR-TCR Summit 2018

Sep 5, 2018 at 11:15 AM EDT


Additional Information

Isaac Ciechanover, M.D., the Company's President and Chief Executive Officer, will participate in a session titled “Next Generation CAR-TCR Therapies: Executive Leaders’ Fireside Chat” on Thursday, September 6, 2018 at 9:30 a.m. EDT.

 

Dietmar Berger, M.D., Ph.D., the Company's Global Head of Research and Development, will give a presentation titled, “Phase 3 Development of tabcel ™, An Off-the-Shelf, Allogeneic T-Cell Immunotherapy for Epstein- Barr Virus Associated Lymphoma” on Wednesday, September 5, 2018 at 11:15 a.m. EDT.

 

Chris Haqq, M.D., Ph.D., the Company's Executive Vice President of Research and Development and Chief Scientific Officer, will participate in a session titled, “Methods to Predict CAR-T Therapy Patient Response to Inform Patient Selection and Trial Design” on Wednesday, September 5, 2018 at 5:15 p.m. EDT.

 

Gad Soffer, the Company's Executive Vice President, Chief Strategy Officer, will participate in a session titled, “How Can We Create a Streamlined Transport and Logistics Chain from Receiving Patient Material to Delivery of Therapy” on Thursday, September 6, 2018 at 2:35 p.m. EDT.

 

The conference will be held at the Seaport Hotel & World Trade Center in Boston, MA.

 

Full Conference Agenda